Bioprocess Capital Ventures
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Bioprocess Capital Ventures
Public Company Edition: Bausch remains the majority shareholder, but B+L is a separate operating company. Also, Rezolute raises $130m in dual financings and BridgeBio outlines job cuts and will out-license assets to conserve cash.
Under deal amendment, Innovent gets Asia rights to Cyramza, Retevmo and pirtobrutinib.
Plus deals involving Neumora/Vanderbilt, Active Biotech/Oncode, and Bridge/Scripps.
Seven international translational research bodies recommend five actions to help better prepare for future outbreaks. Plus an overview of recent COVID-19-focused collaborations.
- Large Molecule
- Other Names / Subsidiaries
- Incuron, Bioprocess Capital Partners